137. Focal cortical dysplasia Disease details / Clinical trials / Drug dev / DR info
Clinical trials : 14 / Drugs : 10 - (DrugBank : 3) / Drug target gene : 1 - Drug target pathways : 49
Drugs, Primary sponsors and Trial info (Enrollment year, Phase, Trial ID, Countries)
Blood and nasal swab sampling
King's College Hospital NHS Trust
2023 - NCT06053671 United Kingdom
Classical ketogenic diet
University College, London
2014 - NCT02261753 Austria;Belgium;Czech Republic;Czechia;France;Germany;Italy;Switzerland;United Kingdom;United States
Everolimus
NYU Langone Health
2014 Phase 2 NCT02451696 United States
Yonsei University
2018 Phase 2 NCT03198949 Korea, Republic of
Radiprodil
GRIN Therapeutics, Inc.
2024 Phase 1/Phase 2 NCT06392009 Australia;Belgium;Canada;Italy;Netherlands;Poland;Spain;United Kingdom
Radiprodil + CO-administered drugs
GRIN Therapeutics, Inc.
2025 Phase 1 NCT06975605 Australia
Radiprodil with carbamazepine
GRIN Therapeutics, Inc.
2025 Phase 1 NCT06965881 Australia
Radiprodil with itraconazole
GRIN Therapeutics, Inc.
2025 Phase 1 NCT06965881 Australia
Rapamune 1 MG/ML oral solution
The Children's Memorial Health Institute
- Phase 2 EUCTR2021-006702-78-PL Poland
Rapamune 1MG/ML oral solution
The Children's Memorial Health Institute
- Phase 2 EUCTR2021-006702-78-PL Poland
Sirolimus
Hokkaido University Hospital
2018 - JPRN-UMIN000030962 Japan
Hokkaido University Hospital Nishi-Niigata Chuo National Hospital National Center Hospital, NCNP Shizuoka Institute of Epilepsy and Neurological Disorders Okayama University Hospital
2018 Phase 2 JPRN-UMIN000033504 Japan
Kato Mituhiro
2023 Phase 3 JPRN-jRCT2031230317 -
Kato Mitsuhiro
2019 Phase 2 JPRN-jRCTs031190157 -
National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, NHO
2017 Phase 2 JPRN-UMIN000030797 Japan
Takahashi Yukitoshi
2019 Phase 2 JPRN-jRCTs041190059 -
King's College Hospital NHS Trust
2023 - NCT06053671 United Kingdom
Classical ketogenic diet
University College, London
2014 - NCT02261753 Austria;Belgium;Czech Republic;Czechia;France;Germany;Italy;Switzerland;United Kingdom;United States
Everolimus
NYU Langone Health
2014 Phase 2 NCT02451696 United States
Yonsei University
2018 Phase 2 NCT03198949 Korea, Republic of
Radiprodil
GRIN Therapeutics, Inc.
2024 Phase 1/Phase 2 NCT06392009 Australia;Belgium;Canada;Italy;Netherlands;Poland;Spain;United Kingdom
Radiprodil + CO-administered drugs
GRIN Therapeutics, Inc.
2025 Phase 1 NCT06975605 Australia
Radiprodil with carbamazepine
GRIN Therapeutics, Inc.
2025 Phase 1 NCT06965881 Australia
Radiprodil with itraconazole
GRIN Therapeutics, Inc.
2025 Phase 1 NCT06965881 Australia
Rapamune 1 MG/ML oral solution
The Children's Memorial Health Institute
- Phase 2 EUCTR2021-006702-78-PL Poland
Rapamune 1MG/ML oral solution
The Children's Memorial Health Institute
- Phase 2 EUCTR2021-006702-78-PL Poland
Sirolimus
Hokkaido University Hospital
2018 - JPRN-UMIN000030962 Japan
Hokkaido University Hospital Nishi-Niigata Chuo National Hospital National Center Hospital, NCNP Shizuoka Institute of Epilepsy and Neurological Disorders Okayama University Hospital
2018 Phase 2 JPRN-UMIN000033504 Japan
Kato Mituhiro
2023 Phase 3 JPRN-jRCT2031230317 -
Kato Mitsuhiro
2019 Phase 2 JPRN-jRCTs031190157 -
National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, NHO
2017 Phase 2 JPRN-UMIN000030797 Japan
Takahashi Yukitoshi
2019 Phase 2 JPRN-jRCTs041190059 -